跳转至内容
Merck
CN
  • Acute treatment with valproic acid and l-thyroxine ameliorates clinical signs of experimental autoimmune encephalomyelitis and prevents brain pathology in DA rats.

Acute treatment with valproic acid and l-thyroxine ameliorates clinical signs of experimental autoimmune encephalomyelitis and prevents brain pathology in DA rats.

Neurobiology of disease (2014-08-26)
Gonçalo Castelo-Branco, Pernilla Stridh, André Ortlieb Guerreiro-Cacais, Milena Z Adzemovic, Ana Mendanha Falcão, Monica Marta, Rasmus Berglund, Alan Gillett, Kedir Hussen Hamza, Hans Lassmann, Ola Hermanson, Maja Jagodic
摘要

Multiple sclerosis (MS) is the most common chronic inflammatory demyelinating disease of the central nervous system (CNS) in young adults. Chronic treatments with histone deacetylase inhibitors (HDACis) have been reported to ameliorate experimental autoimmune encephalomyelitis (EAE), a rodent model of MS, by targeting immune responses. We have recently shown that the HDAC inhibition/knockdown in the presence of thyroid hormone (T3) can also promote oligodendrocyte (OL) differentiation and expression of myelin genes in neural stem cells (NSCs) and oligodendrocyte precursors (OPCs). In this study, we found that treatment with an HDACi, valproic acid (VPA), and T3, alone or in combination, directly affects encephalitogenic CD4+ T cells. VPA, but not T3, compromised their proliferation, while both molecules reduced the frequency of IL-17-producing cells. Transfer of T3, VPA and VPA/T3 treated encephalitogenic CD4+ T cells into naïve rats induced less severe EAE, indicating that the effects of these molecules are persistent and do not require their maintenance after the initial stimuli. Thus, we investigated the effect of acute treatment with VPA and l-thyroxine (T4), a precursor of T3, on myelin oligodendrocyte glycoprotein-induced EAE in Dark Agouti rats, a close mimic of MS. We found that a brief treatment after disease onset led to sustained amelioration of EAE and prevention of inflammatory demyelination in the CNS accompanied with a higher expression of myelin-related genes in the brain. Furthermore, the treatment modulated immune responses, reduced the number of CD4+ T cells and affected the Th1 differentiation program in the brain. Our data indicate that an acute treatment with VPA and T4 after the onset of EAE can produce persistent clinically relevant therapeutic effects by limiting the pathogenic immune reactions while promoting myelin gene expression.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
甲醇, suitable for HPLC, ≥99.9%
Sigma-Aldrich
甲醇, ACS reagent, ≥99.8%
Sigma-Aldrich
甲醇, suitable for HPLC, gradient grade, ≥99.9%
Sigma-Aldrich
甲醇, HPLC Plus, ≥99.9%
Sigma-Aldrich
甲醇, anhydrous, 99.8%
Sigma-Aldrich
L-谷氨酰胺, meets USP testing specifications, suitable for cell culture, 99.0-101.0%, from non-animal source
Sigma-Aldrich
甲醇, Laboratory Reagent, ≥99.6%
Sigma-Aldrich
甲醇, suitable for HPLC, gradient grade, suitable as ACS-grade LC reagent, ≥99.9%
Sigma-Aldrich
甲醇, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99.8% (GC)
Sigma-Aldrich
L-谷氨酰胺, ReagentPlus®, ≥99% (HPLC)
Sigma-Aldrich
甲醇, ACS spectrophotometric grade, ≥99.9%
Sigma-Aldrich
丙戊酸 钠盐, 98%
Sigma-Aldrich
甲醇, ACS reagent, ≥99.8%
Sigma-Aldrich
丙酮酸, 98%
SAFC
L-谷氨酰胺
USP
木精, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
甲醇, BioReagent, ≥99.93%
Supelco
甲醇, analytical standard
Supelco
甲醇, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
甲醇, ACS reagent, ≥99.8%
Sigma-Aldrich
L-甲状腺素, ≥98% (HPLC)
Sigma-Aldrich
L-谷氨酰胺, BioUltra, ≥99.5% (NT)
Sigma-Aldrich
丙酮酸, ≥97%, FG
USP
L-甲状腺素, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
丙酮酸, 95%
Sigma-Aldrich
L-谷氨酰胺, γ-irradiated, BioXtra, suitable for cell culture
Sigma-Aldrich
L-谷氨酰胺
Sigma-Aldrich
丙酮酸, natural, ≥95%, FG
Sigma-Aldrich
甲醇, puriss., meets analytical specification of Ph Eur, ≥99.7% (GC)
Supelco
L-谷氨酰胺, Pharmaceutical Secondary Standard; Certified Reference Material